An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023.

Brendan Mcdermid | Reuters

Eli Lilly‘s weight-loss drug Zepbound showed promise as a treatment for sleep apnea — giving investors more confidence to keep owning the world’s most valuable health-care company even after it’s been crushing the S&P 500’s performance over the past three years.

Source link